Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Studies on Alcohol and Drugs

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.15288/JSAD.2012.73.991PMID 23036218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals

  2012cited by this paper
• Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

  2011cited by this paper
• Intramuscular extended‐release naltrexone: current evidence

  2011cited by this paper
• Clinical syndromes and consequences of antiretroviral‐related hepatotoxicity

  2010cited by this paper
• Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

  2010cited by this paper
• Liver tests are irrelevant when prescribing statins.

  2010cited by this paper
• Risk factors for idiosyncratic drug-induced liver injury.

  2010cited by this paper
• The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.

  2009cited by this paper
• Biomarkers for the Diagnosis and Management of Drug-Induced Liver Injury

  2009cited by this paper
• Naltrexone for the management of alcohol dependence.

  2008cited by this paper
• Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.

  2008cited by this paper
• Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.

  2007cited by this paper
• Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.

  2007cited by this paper
• Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

  2006cited by this paper
• Pharmacokinetics of Long‐Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment

  2005cited by this paper
• Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

  2005cited by this paper
• Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.

  2004cited by this paper
• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

  2004cited by this paper
• Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance

  2004cited by this paper
• Isoniazid hepatotoxicity among drug users: the role of hepatitis C.

  2003cited by this paper
• Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections

  2002cited by this paper
• Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

  2001cited by this paper
• Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

  2000cited by this paper
• A prospective, community‐based evaluation of liver enzymes in individuals with hepatitis C after drug use

  1999cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.

  1998cited by this paper
• Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.

  1996cited by this paper
• Lack of Hepatotoxicity with Naltrexone Treatment

  1994cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1992cited by this paper
• Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

  1992cited by this paper
• Naltrexone: Lack of Effect on Hepatic Enzymes

  1988cited by this paper
• High-dose naltrexone therapy and dietary counseling for obesity.

  1987cited by this paper
• Effects of long‐term therapy with naltrexone on body weight in obesity

  1985cited by this paper
• Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.

  1975cited by this paper

• Perspectives of Opportunities and Barriers: Department of Corrections Extended-Release Naltrexone Program Evaluation

  2025cites this paper
• Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease

  2025cites this paper
• Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder

  2024cites this paper
• Safety and Effectiveness of Naltrexone in the Management of Alcohol Use Disorder in Patients With Alcohol-associated Cirrhosis: First Clinical Observation From Indian Cohort.

  2024cites this paper
• Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

  2024cites this paper
• Medication treatment for alcohol use disorder in special populations.

  2023cites this paper
• Extended-release Naltrexone Is Not Linked to Hepatotoxicity in Adults Experiencing Homelessness and Alcohol Use Disorder

  2023cites this paper
• Multidisciplinary Care of Alcohol-Related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians.

  2023cites this paper
• Treatment of Opioid Use Disorder in the General Hospital.

  2023cites this paper
• Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs

  2021cites this paper
• Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV

  2021cites this paper
• Inpatient opioid use disorder treatment for the infectious disease physician

  2021cites this paper
• Naltrexone Implant for Opioid Use Disorder

  2021influential citation
• Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder?

  2021cites this paper
• Effects of Medication-Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes: A Systematic Review.

  2020cites this paper
• Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.

  2019cites this paper
• Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV.

  2019cites this paper
• Medications for Treatment of Opioid Use Disorder among Persons Living with HIV

  2019cites this paper
• Addressing Host Factors: Primary, Secondary, and Tertiary Prevention of Opioid Dependence

  2018cites this paper
• Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease

  2018cites this paper
• Liver toxicity of Naltrexone. a case study and review of literature

  2018cites this paper
• Alcohol addiction - the safety of available approved treatment options

  2018cites this paper
• Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial

  2017cites this paper
• Update on pharmacotherapy for treatment of opioid use disorder

  2016cites this paper
• Opioid use and risk of liver fibrosis in HIV/hepatitis C virus‐coinfected patients in Canada

  2016cites this paper
• Unhealthy Alcohol Use.

  2016cites this paper
• Treatment of Opioid-Use Disorders.

  2016cites this paper
• Treatment of Opioid-Use Disorders.

  2016cites this paper
• Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C

  2015cites this paper
• Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions

  2015cites this paper
• Naltrexone: Not Just for Opioids Anymore

  2015cites this paper
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.

  2014cites this paper
• An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.

  2014cites this paper
• Extended-Release Intramuscular Naltrexone (VIVITROL®): A Review of Its Use in the Prevention of Relapse to Opioid Dependence in Detoxified Patients

  2013influential citation
• Symptoms of depression and PTSD are associated with elevated alcohol demand.

  2013cites this paper
• [Long-acting naltrexone--a new way out of opiate addiction?].

  2013cites this paper
• Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)

  2013cites this paper
• Endogenous opiates and behavior: 2012.

  2013cites this paper
• Elevated Liver Enzymes with Naltrexone Might Not Indicate Toxicity

  2012cites this paper